[Correspondence] Cardiovascular risk in hypertension: open questions about HOPE 4 – Authors’ reply

Summary: We thank Marleen Hendriks and colleagues and Adam Richards for their comments regarding the HOPE 4 trial.1 Hendriks and colleagues draw attention to the generalisability of our findings as the non-physician health workers were paid by the project and the study medications were provided to the intervention group free of charge. Although working within the infrastructure of existing health-care systems might be theoretically optimal for uptake and sustainability, most health systems do not adequately address cardiovascular disease control.

Source: The Lancet

Read More

Be the first to comment

Leave a Reply

Your email address will not be published.